Bristol Myers Return On Assets History
| BMY Stock | USD 58.71 -0.31 -0.53% |
Return On Assets | First Reported 2010-12-31 | Previous Quarter 0.07833359 | Current Value 0.07833359 | Quarterly Volatility 0.06717433 |
Macro event markers
Latest Bristol Myers Return On Assets Growth Pattern
| Return On Assets | 10 Years Trend |
|
Return On Assets |
| Timeline |
Return On Assets Trend Statistics
A CV of 107.4% for Bristol Myers' Return On Assets indicates elevated dispersion relative to the mean over 15 periods. The R-squared value of 0.08 is consistent with no statistically meaningful linear trend.| Arithmetic Mean | 0.06 | |
| Geometric Mean | 0.07 | |
| Coefficient Of Variation | 107.42 | |
| Mean Deviation | 0.05 | |
| Median | 0.07 | |
| Standard Deviation | 0.07 | |
| Sample Variance | 0.0045 | |
| Range | 0.2388 | |
| R-Value | -0.28 | |
| Mean Square Error | 0.0044 | |
| R-Squared | 0.08 | |
| Significance | 0.28 | |
| Slope | -0.0037 | |
| Total Sum of Squares | 0.07 |
Bristol Myers Return On Assets History
Bristol Myers' Return On Assets record extends from 2010 to 2025, covering 15 observations from 0.14 to 0.0783.| 2025 | 0.0783 | ||
| 2024 | -0.0966 | ||
| 2023 | 0.0843 | ||
| 2022 | 0.0653 | ||
| 2021 | 0.064 | ||
| 2020 | -0.0759 | ||
| 2019 | 0.0265 | ||
| 2017 | 0.03 | ||
| 2016 | 0.13 | ||
| 2015 | 0.0493 | ||
| 2014 | 0.0594 | ||
| 2013 | 0.0664 | ||
| 2012 | 0.0546 | ||
| 2011 | 0.11 | ||
| 2010 | 0.14 |
Correlation of Return On Assets With Other Accounts
Linear correlations between Return On Assets and other accounts within Bristol Myers' reporting history are shown below. Strong correlations may reflect underlying operational relationships or scaling effects across related metrics.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Return On Tangible Assets | 0.14 | 0.15 | |
| Return On Capital Employed | 0.19 | 0.28 | |
| Return On Equity | 38.18% | 29.00% |
Methodology, Assumptions & Data Sources
A longitudinal view of Bristol Myers's Return On Assets is provided for trend analysis. Mean-reversion tendencies in this metric suggest cyclical operating drivers rather than a permanent shift in trajectory. Bristol Myers' Return On Assets is shaped by investment and capital allocation patterns characteristic of the Pharmaceuticals sector.
Bristol Myers Squibb inputs come from periodic company reporting and market reference feeds and are mapped into a consistent reporting framework. Analyst inputs may be included when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Vlad Skutelnik, Macroaxis Contributor